Research & Education

New Frontiers in the Management of Lung Cancer

Thursday, January 7, 2016 at 6 p.m. HKT - Recording Available

 

Tony Mok Nayer Rizvi Daniel Tan 

Program Chair
Professor Tony Mok, MD

Chairman, Department of
Clinical Oncology
The Chinese University
of Hong Kong

Nayer Rizvi, MD

Director, Thoracic
Oncology & Phase I
Immunotherapeutics
Columbia University
Medical Center,
New York

Daniel S.W. Tan, MD
 
Consultant Medical
Oncologist
National Cancer
Centre Singapore

 INTERNET ENDURING MATERIAL

Name of Reviewer(s): 

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

Deb Whippen- Nothing to Disclose

Name of Activity: 

New Frontiers in the Management of Lung Cancer

Date of Activity:

January 07, 2016

Faculty/Speaker(s):

Tony Mok, MD, PhD- Hong Kong- Nothing to Disclose

Nayer Rizvi, MD- USA- Nothing to Disclose

Daniel S. W. Tan, MD- Singapore- Nothing to Disclose

Type of Activity: 

 Direct Provided

  Internet Live Course

1 Hour to Complete

Are there Commercial Supporters for this activity?

   YES

If yes, please list:Grant Support from ROCHE Hong Kong

The Imminent Impact of Immunotherapy: Nayer Rizvi, MD
With the U.S. approvals of nivolumab and pembrolizumab for pretreated NSCLC and also the release of PD-L1 diagnostic tests in the U.S., we will discuss the impact of these drug and diagnostic test approvals and how they are impacting the current landscape of NSCLC treatment. The future landscape is approaching rapidly with ongoing registrational studies in first line NSCLC and these trials may alter the first line space in the very near future.

Rapid Changes in the Choice of Molecular Targeted Therapy: Daniel S.W. Tan, MD
With the expanding repertoire of druggable targets and rapid approvals of next generation EGFR and ALK inhibitors, this presentation will cover some of the key clinical considerations in selecting these drugs in the treatment of NSCLC. It will also discuss some of the emerging combination approaches to overcome drug resistance and the use of novel trial design and biomarkers to address this.

Clinical Applicability of Plasma-Based Genomic Testing: Professor Tony Mok, MD
EGFR mutation testing is essential to personalized medicine for lung cancer, however, tumor samples with adequate DNA contents are not always available. Plasma cfDNA is an excellent alternative that is associated with a reasonable sensitivity and high specificity. This presentation will summarize the existing data on genomic testing on plasma cfDNA at the time of diagnosis for treatment selection, monitoring and identification of resistant oncogene (exon 20 T790M). In addition, we shall also explore the feasibility of NGS on cfDNA for detection of the uncommon actionable oncogenes.

 

At the end of this activity learners will be able to:

  1. Classify clinical developments and evolving standards impacting the management of advanced stage non-small cell lung cancer.

  2. Articulate some of the key clinical considerations in selecting drugs in the treatment of non- small cell lung cancer.

  3. Explore the feasibility of NGS on cfDNA for detection of the uncommon actionable oncogenes.

CME Information:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

The objective of this activity is to enable fruitful collaborations that could help design a high priority biomarker-driven clinical study to assess the efficacy of a targeted-therapy in a specific lung cancer population, while helping to collect data for regulatory approval.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

IASLC Financial/Commercial Relationship and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

DOWNLOAD RECORDING

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Thursday, January 7, 2016 at 5:00:00 AM EST UTC-5 hours
Hong Kong (Hong Kong) Thursday, January 7, 2016 at 6:00:00 PM HKT UTC+8 hours
Beijing (China) Thursday, January 7, 2016 at 6:00:00 PM CST UTC+8 hours
Kuala Lumpur (Malaysia) Thursday, January 7, 2016 at 6:00:00 PM MYT UTC+8 hours
Shanghai (China) Thursday, January 7, 2016 at 6:00:00 PM CST UTC+8 hours
Tokyo (Japan) Thursday, January 7, 2016 at 7:00:00 PM JST UTC+9 hours
Taipei (Taiwan) Thursday, January 7, 2016 at 6:00:00 PM CST UTC+8 hours
Bangkok (France) Thursday, January 7, 2016 at 5:00:00 PM ICT UTC+7 hours
Corresponding UTC (GMT) Thursday, January 7, 2016 at 10:00:00 AM    

How to use the Time Zone Converter

IASLC gratefully acknowledges an unrestricted grant from Roche Hong Kong in partial support of this program.